Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis

被引：1
作者：
Lie, Ingrid Anne [1 ,2 ]
Rod, Brit Ellen [1 ,2 ]
Kvistad, Silje Stokke [2 ,3 ]
Holmoy, Trygve [4 ,5 ]
Myhr, Kjell-Morten [1 ,2 ]
Torkildsen, Oivind [1 ,2 ]
Wergeland, Stig [1 ,2 ,6 ]
机构：
[1] Univ Bergen, Dept Clin Med, Bergen, Norway
[2] Haukeland Hosp, Dept Neurol, Neurosysmed, Bergen, Norway
[3] Haukeland Hosp, Dept Immunol & Transfus Med, Bergen, Norway
[4] Univ Oslo, Inst Clin Med, Oslo, Norway
[5] Akershus Univ Hosp, Dept Neurol, Lorenskog, Norway
[6] Haukeland Hosp, Norwegian MS Registry & Biobank, Bergen, Norway
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2023年 / 70卷
关键词：
Multiple sclerosis; Interferons; Epstein-Barr virus; Herpesviridae; EBNA-1; DISEASE-ACTIVITY; THERAPY; EBV;
D O I：
10.1016/j.msard.2023.104530
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
There is increasing evidence of Epstein-Barr virus (EBV) being conditional in multiple sclerosis (MS) pathogenesis and influential for disease activity. Interferon-beta (IFN beta) is a cytokine with antiviral effects used to treat MS, in which a possible antiviral effect against EBV has been questioned. In this study, we investigated the effect of IFN beta-1a treatment on serum EBV antibody levels in 84 patients with relapsing-remitting MS. In the 18 months following IFN beta-1a treatment initiation, there were no significant associations between treatment and serum levels of Epstein-Barr nuclear antigen 1 (EBNA-1) immunoglobulin (Ig) G, early antigen (EA) IgG, viral capsid antigen (VCA) IgG or VCA IgM. The findings suggest that IFN beta-1a treatment does not influence the humoral response to EBV in patients with MS.
引用
收藏
页数：3
相关论文
共 19 条
  • [11] Multiple sclerosis therapy and Epstein-Barr virus antibody titres
    Raffel, Joel
    Dobson, Ruth
    Gafson, Arie
    Mattoscio, Miriam
    Muraro, Paolo
    Giovannoni, Gavin
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2014, 3 (03) : 372 - 374
  • [12] Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis
    Rizzo, Fabiana
    Giacomini, Elena
    Mechelli, Rosella
    Buscarinu, Maria Chiara
    Salvetti, Marco
    Severa, Martina
    Coccia, Eliana Marina
    [J]. IMMUNOLOGY AND CELL BIOLOGY, 2016, 94 (09) : 886 - 894
  • [13] Antiviral actions of interferons
    Samuel, CE
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (04) : 778 - 809
  • [14] Revisiting the antiviral theory to explain interferon-beta's effectiveness for relapsing multiple sclerosis
    Sedaghat, Nahad
    Etemadifar, Masoud
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 67
  • [15] Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis
    Sundstrom, Peter
    Nystrom, Maria
    Ruuth, Kristina
    Lundgren, Erik
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2009, 215 (1-2) : 102 - 107
  • [16] ω-3 Fatty Acid Treatment in Multiple Sclerosis (OFAMS Study) A Randomized, Double-Blind, Placebo-Controlled Trial
    Torkildsen, Oivind
    Wergeland, Stig
    Bakke, Soren
    Beiske, Antonie G.
    Bjerve, Kristian S.
    Hovdal, Harald
    Midgard, Rune
    Lilleas, Finn
    Pedersen, Tom
    Bjornara, Bard
    Dalene, Froydis
    Kleveland, Grethe
    Schepel, Jan
    Olsen, Inge Christoffer
    Myhr, Kjell-Morten
    [J]. ARCHIVES OF NEUROLOGY, 2012, 69 (08) : 1044 - 1051
  • [17] Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients
    Wergeland, S.
    Myhr, K. -M.
    Loken-Amsrud, K. I.
    Beiske, A. G.
    Bjerve, K. S.
    Hovdal, H.
    Midgard, R.
    Kvistad, S. S.
    Holmoy, T.
    Riise, T.
    Torkildsen, O.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 (06) : 1064 - 1070
  • [18] Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study
    Zivadinov, Robert
    Jakimovski, Dejan
    Ramanathan, Murali
    Benedict, Ralph HB.
    Bergsland, Niels
    Dwyer, Michael G.
    Weinstock-Guttman, Bianca
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 67
  • [19] Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis
    Zivadinov, Robert
    Ramanathan, Murali
    Hagemeier, Jesper
    Bergsland, Niels
    Ramasamy, Deepa P.
    Durfee, Jacqueline
    Kolb, Channa
    Weinstock-Guttman, Bianca
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 36
12